Ken Reali was appointed CEO of Bioventus in April 2020. Prior to that, Reali served as President and CEO of Clinical Innovations, a medical device company focused in woman’s healthcare, from June 2015 until its successful sale in Q1 of 2020.
During his twenty-nine-year medical device career, he has gained significant experience in product development, global marketing, business development, commercialization and sales of medical devices. He has a strong background in ethics and compliance, market analysis, reimbursement strategy, regulatory and clinical affairs, new product development, sales force optimization and domestic and international product commercialization.
As a CEO, Reali has gained experience working with medical societies, patient advocacy groups, governmental agencies, public and private insurance companies, investor relations, capital funding, strategic planning and acquisitions and quality and lean production and operations. He started his career at Biomet and worked at Stryker, Smith & Nephew and Baxano Surgical where he held positions of increasing responsibility including CEO over the past ten years.
Reali also serves on the board of Ossio Integrative Orthopedics, the board of AdvaMed and the board of Dysis Medical, a woman’s healthcare company. He previously served as Chairman of the Ethics and Compliance Committee for AdvaMed and as a board member of AdvaMed Accel.
What is Kenneth Michael Reali's net worth?
The estimated net worth of Kenneth Michael Reali is at least $120,640.85 as of March 15th, 2023. Mr. Reali owns 30,085 shares of Bioventus stock worth more than $120,641 as of April 26th. This net worth approximation does not reflect any other assets that Mr. Reali may own. Learn More about Kenneth Michael Reali's net worth.
How do I contact Kenneth Michael Reali?
Has Kenneth Michael Reali been buying or selling shares of Bioventus?
Kenneth Michael Reali has not been actively trading shares of Bioventus during the past quarter. Most recently, Kenneth Michael Reali sold 9,811 shares of the business's stock in a transaction on Wednesday, March 15th. The shares were sold at an average price of $1.39, for a transaction totalling $13,637.29. Following the completion of the sale, the chief executive officer now directly owns 30,085 shares of the company's stock, valued at $41,818.15. Learn More on Kenneth Michael Reali's trading history.
Who are Bioventus' active insiders?
Are insiders buying or selling shares of Bioventus?
In the last twelve months, Bioventus insiders bought shares 10 times. They purchased a total of 2,252,180 shares worth more than $5,586,079.33. In the last twelve months, insiders at the sold shares 5 times. They sold a total of 16,114 shares worth more than $81,550.01. The most recent insider tranaction occured on April, 11th when CFO Mark Leonard Singleton sold 4,000 shares worth more than $19,000.00. Insiders at Bioventus own 29.1% of the company.
Learn More about insider trades at Bioventus. Information on this page was last updated on 4/11/2024.
